Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 3/2021

01.03.2021 | Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Progress Update in Pediatric Renal Tumors

verfasst von: Juhi Jain, Kathryn S. Sutton, Andrew L. Hong

Erschienen in: Current Oncology Reports | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pediatric renal tumors account for 7% of new cancer diagnoses in children. Here, we will review results from recently completed clinical trials informing the current standard of care and discuss targeted and immune therapies being explored for the treatment of high risk or relapsed/refractory pediatric renal malignancies.

Recent Findings

Cooperative group trials have continued to make improvements in the care of children with pediatric tumors. In particular, trials that standardize treatment of rare cancers (e.g., bilateral Wilms tumor) have improved outcomes significantly.

Summary

We have seen improvements in event free and overall survival in recently completed clinical trials for many pediatric renal tumors. Still, there are subsets of rarer cancers where outcomes remain poor and new therapeutic strategies are needed. Future trials aim to balance treatment toxicity with treatment efficacy for those with excellent outcomes while identifying novel therapeutics for those with poor outcomes.
Literatur
1.
Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) SEER*Explorer database: incidence - SEER research data, kidney and renal pelvis cancer SEER incidence rates by age at diagnosis, Sub (2013-2017), National Cancer Institute, DCCPS, Surveillance Research Program. https://​seer.​cancer.​gov/​explorer/​application.​html?​site = 72&data_type = 1&graph_type = 3&compareBy = sex&chk_sex_1 = 1&chk_sex_3 = 3&chk_sex_2 = 2&race = 1&rate_type = 1&advopt_precision = 1&advopt_display = 2. Accessed 7 Aug 2020
2.
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, et al. Children’s Oncology Group’s 2013 blueprint for research: renal tumors. Pediatr Blood Cancer. 2013;60:994–1000.
3.
D’Angio GJ. The National Wilms tumor study: a 40 year perspective. Lifetime Data Anal. 2007;13:463–70.CrossRef
4.
Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43:705–15.CrossRef
5.
Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, et al. Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3195–203.
6.
Wright KD, Green DM, Daw NC. Late effects of treatment for Wilms tumor. Pediatr Hematol Oncol. 2009;26:407–13.CrossRef
7.
Lu Y-J, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K, et al. chromosome 1q expression profiling and relapse in Wilms’ tumour. Lancet Lond Engl. 2002;360:385–6.
8.
Bown N, Cotterill SJ, Roberts P, Griffiths M, Larkins S, Hibbert S, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children’s Cancer Study Group. Med Pediatr Oncol. 2002;38:11–21.
9.
Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors. Am J Pathol. 2001;158:393–8.
10.
Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006;210:49–58.
11.
Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms’ tumour. J Pathol. 2007;211:52–9.
12.
Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer. 2004;41:65–79.
13.
Huang C-C, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children’s Oncology Group. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:1770–8.
14.
Segers H, van den Heuvel-Eibrink MM, Williams RD, van Tinteren H, Vujanic G, Pieters R, et al. Gain of 1q is a marker of poor prognosis in Wilms’ tumors. Genes Chromosomes Cancer. 2013;52:1065–74.
15.
Gratias EJ, Jennings LJ, Anderson JR, Dome JS, Grundy P, Perlman EJ. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children’s Oncology Group. Cancer. 2013;119:3887–94.CrossRef
16.
Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, et al. Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children’s Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3189–94.
17.•
Dix DB, Fernandez CV, Chi Y-Y, et al. Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2769–77 This reference utilizes the most current studies for FHWT to analyze the effect of augmentation of therapy for those patients with LOH 1p and 16q.CrossRef
18.••
Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer. 2014;120:2497–506.CrossRef
19.
Fernandez CV, Perlman EJ, Mullen EA, et al. Clinical outcome and biological predictors of relapse after nephrectomy only for very low-risk Wilms tumor. Ann Surg. 2017;265:835–40 This reference utilizes the most current studies for very low-risk FHWT to analyze the effect of reducing therapy and analyzing markers for risk of relapse.
20.
Parsons LN, Mullen EA, Geller JI, Chi YY, Khanna G, Glick RD, et al. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: a report from Children’s Oncology Group study AREN03B2. Cancer. 2020;126:2866–71.
21.••
Fernandez CV, Mullen EA, Chi Y-Y, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group Study AREN0532. J Clin Oncol. 2018;36:254–61 This reference utilizes the most current studies for Stage III FHWT to analyze the effect of augmenting therapy.CrossRef
22.
Verschuur A, Van Tinteren H, Graf N, Bergeron C, Sandstedt B, de Kraker J. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3533–9.CrossRef
23.••
Dix DB, Seibel NL, Chi Y-Y, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol. 2018;36:1564–70 This reference utilizes the most current studies for Stage IV FHWT to analyze the effect of augmenting therapy, decreasing radiation for a subset of patients and analyzing the effect of 1q gain.CrossRef
24.••
Ehrlich PF, Chi Y-Y, Chintagumpala MM, et al. Results of the first prospective multi-institutional treatment study in children with bilateral Wilms tumor (AREN0534): a report from the Children’s Oncology Group. Ann Surg. 2017;266:470–8 This reference utilizes the most current studies for bilateral Wilms to analyze the effect of augmenting therapy and utilizing nephron sparing surgery to preserve renal tissue/function.CrossRef
25.
Ooms AHAG, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, et al. Significance of TP53 mutation in Wilms tumors with diffuse anaplasia: a report from the Children’s Oncology Group. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:5582–91.
26.••
Daw NC, Chi Y-Y, Kim Y, et al. Treatment of stage I anaplastic Wilms’ tumour: a report from the Children’s Oncology Group AREN0321 study. Eur J Cancer Oxf Engl 1990. 2019;118:58–66 This reference utilizes the most current studies for AWT to analyze the effect of augmenting therapy.
27.
Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, et al. Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:2352–8.
28.
Fajardo RD, van den Heuvel-Eibrink MM, van Tinteren H, et al. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG. Pediatr Blood Cancer. 2020;67:e28039.CrossRef
29.••
Daw NC, Chi Y-Y, Kalapurakal JA, et al. Activity of vincristine and irinotecan in diffuse anaplastic Wilms tumor and therapy outcomes of stage II to IV disease: results of the Children’s Oncology Group AREN0321 study. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1558–68 This reference utilizes the most current studies for Stage II-IV DAWT to analyze the effect of augmenting therapy.CrossRef
30.
Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015;27:286–97.
31.
Wegert J, Zauter L, Appenzeller S, Otto C, Bausenwein S, Vokuhl C, et al. High-risk blastemal Wilms tumor can be modeled by 3D spheroid cultures in vitro. Oncogene. 2020;39:849–61.
32.
Murphy AJ, Chen X, Pinto EM, Williams JS, Clay MR, Pounds SB, et al. Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nat Commun. 2019;10:5806.
33.
34.
Hingorani P, Zhang W, Kurmasheva RT, Zhang Z, Wang Y Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS- 8201a), a HER2 antibody drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). 1
35.
Kurmasheva RT, Kurmashev D, Reynolds CP, Kang M, Wu J, Houghton PJ, et al. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2018;65. https://​doi.​org/​10.​1002/​pbc.​26825.
36.
Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, et al. The classification of pediatric and young adult renal cell carcinomas registered on the children’s oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124:3381–9.
37.••
Geller JI, Cost NG, Chi Y-Y, et al (2020) A prospective study of pediatric and adolescent renal cell carcinoma: a report from the Children’s Oncology Group AREN0321 study. Cancer. 2020;126:5156–64. https://​doi.​org/​10.​1002/​cncr.​33173This paper summarizes the first prospective study to further understand the landscape of pediatric RCC
38.
Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:1834–8.
39.
Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.
40.
Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16:577–80.
41.
Pwint TP, Macaulay V, Roberts ISD, Sullivan M, Protheroe A. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2011;29:821–4.CrossRef
42.
Chowdhury T, Prichard-Jones K, Sebire NJ, Bier N, Cherian A, Sullivan MO, et al. Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. J Pediatr Hematol Oncol. 2013;35:e1–3.
43.
Ambalavanan M, Geller JI. Treatment of advanced pediatric renal cell carcinoma. Pediatr Blood Cancer. 2019;66:e27766.CrossRef
44.
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet Lond Engl. 2011;378:1931–9.
45.
46.
Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67:507–24.CrossRef
47.
Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015;41:114–21.
48.
McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2013–20.CrossRef
49.
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1430–7.CrossRef
50.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15.
51.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.
52.
53.
Carugo A, Minelli R, Sapio L, et al. p53 Is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors. Cancer Cell. 2019;35:204–220.e9.CrossRef
54.••
Gooskens SLM, Furtwängler R, Vujanic GM, Dome JS, Graf N, van den Heuvel-Eibrink MM (2012) Clear cell sarcoma of the kidney: a review. Eur J Cancer Oxf Engl 1990 48:2219–2226 This reference describes the UMBRELLA protocol, an international collaborative protocol for the diagnosis, treatment and follow up of childhood renal tumors. This part of the protocol outlines recent studies and plans for CCSK
55.
Argani P, Perlman EJ, Breslow NE, Browning NG, Green DM, D’Angio GJ, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol. 2000;24:4–18.
56.
Aw SJ, Chang KTE. Clear Cell Sarcoma of the Kidney. Arch Pathol Lab Med. 2019;143:1022–6.CrossRef
57.
Wong MK, Ng CCY, Kuick CH, Aw SJ, Rajasegaran V, Lim JQ, et al. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR–CCNB3 gene fusion. Histopathology. 2018;72:320–9.
58.
Gooskens SL, Graf N, Furtwängler R, et al. Rationale for the treatment of children with CCSK in the UMBRELLA SIOP–RTSG 2016 protocol. Nat Rev Urol. 2018;15:309–19.CrossRef
59.
60.
Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet TIG. 2014;30:356–63.CrossRef
61.
Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203–6.
62.
Roberts CWM, Orkin SH. The SWI/SNF complex — chromatin and cancer. Nat Rev Cancer. 2004;4:133–42.CrossRef
63.
Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122:2983–8.
64.
Mora-Blanco EL, Mishina Y, Tillman EJ, Cho Y-J, Thom CS, Pomeroy SL, et al. Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene. 2014;33:933–8.
65.
Wang X, Haswell JR, Roberts CWM. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer—mechanisms and potential therapeutic insights. Clin Cancer Res. 2014;20:21–7.CrossRef
66.
Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, et al. Rhabdoid tumor of the kidney in the National Wilms’ Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7641–5.
67.
Mills CC, Kolb EA, Sampson VB. Review: recent advances of cell cycle inhibitor therapies for pediatric cancer. Cancer Res. 2017;77:6489–98.CrossRef
68.
Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2017;64:e26218. https://​doi.​org/​10.​1002/​pbc.​26218.
69.
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the Aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP). Pediatr Blood Cancer. 2010;55:26–34.
70.
Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, et al. MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors. Cancer Res. 2019;79:2404–14.
71.
72.
Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 2014;26:309–17.CrossRef
73.
Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110:7922–7.
74.
Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22:128–34.CrossRef
75.
Chi S, Fouladi M, Shukla N, et al. Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma. Mol Cancer Ther. 2018;17:A175.CrossRef
76.
Stacchiotti S, Blay J-Y, Jones RL, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Ann Oncol. 2018;29:viii580.CrossRef
77.
Anderson J, Gibson S, Sebire NJ. Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology. 2006;48:748–53.CrossRef
78.
Gooskens SL, Houwing ME, Vujanic GM, Dome JS, Diertens T, Coulomb-l’Herminé A, et al. Congenital mesoblastic nephroma 50 years after its recognition: a narrative review. Pediatr Blood Cancer. 2017;64. https://​doi.​org/​10.​1002/​pbc.​26437.
79.
Lei L, Stohr BA, Berry S, Lockwood CM, Davis JL, Rudzinski ER, et al. Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. Pract Lab Med. 2020;21:e00164.
80.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378:731–9.CrossRef
81.
Halalsheh H, McCarville MB, Neel M, Reynolds M, Cox MC, Pappo AS. Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. Pediatr Blood Cancer. 2018;65:e27271.CrossRef
82.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373:1814–23.
83.
Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108.PubMedPubMedCentral
84.
Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther. 2009;8:1–9.CrossRef
85.
McCubrey JA, Rakus D, Gizak A, et al. Effects of mutations in Wnt/β-catenin, hedgehog, notch and PI3K pathways on GSK-3 activity-diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta. 2016;1863:2942–76.CrossRef
86.
Prossomariti A, Piazzi G, Alquati C, Ricciardiello L. Are Wnt/β-catenin and PI3K/AKT/mTORC1 distinct pathways in colorectal cancer? Cell Mol Gastroenterol Hepatol. 2020;10:491–506.CrossRef
87.
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1928–40.
88.
Coyne GO, Yap TA, Moore N, et al. Abstract B105: phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. Mol Cancer Ther. 2019;18:B105–5.
89.
Morschhauser F, Machiels J-P, Salles G, Rottey S, Rule SAJ, Cunningham D, et al. On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther. 2020;19:468–78.
90.
Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010;70:10310–20.CrossRef
91.
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6.
92.
93.
Shah JJ, Jakubowiak AJ, O’Connor OA, et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:34–43.CrossRef
94.
Swords RT, Erba HP, DeAngelo DJ, et al. Pevonedistat (MLN4924), a First-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169:534–43.CrossRef
95.
Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, et al. Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:847–57.
96.
Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the investigational NEDD8 activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59:246–53. https://​doi.​org/​10.​1002/​pbc.​23357.
97.
Traore T, Mihollen M, Garnsey J, Berger A, Manfredi M, Cosmopolous K, et al. Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma. J Clin Oncol. 2011;29:8594–4.
98.
Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, et al. Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways. Mol Cancer Ther. 2014;13:1625–35.
99.
Foster J, Muscal J, et al. Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615). J Clin Oncol. 2019;37(15)e21521.
100.•
Parsons D, Janeway K, et al. Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. J Clin Oncol. 2019;37(15)10011. This reference describes current outcomes of the NCI-COG Pediatric MATCH that identifies genomic alterations in relapsed/refractory childhood cancers regardless of tumor type and, if an actionable target is identified, recommends treatment with an investigational new drug
Metadaten
Titel
Progress Update in Pediatric Renal Tumors
verfasst von
Juhi Jain
Kathryn S. Sutton
Andrew L. Hong
Publikationsdatum
01.03.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 3/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01016-y

Weitere Artikel der Ausgabe 3/2021

Current Oncology Reports 3/2021 Zur Ausgabe

Head and Neck Cancers (EY Hanna, Section Editor)

Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality

Neuro-oncology (KS Nevel, Section Editor)

Updates on Surgical Management and Advances for Brain Tumors

Breast Cancer (B Overmoyer, Section Editor)

Psychological Aspects to Consider in Breast Cancer Diagnosis and Treatment

Evolving Therapies (RM Bukowski, Section Editor)

Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs

Neuro-oncology (KS Nevel, Section Editor)

Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise